By Kimberly Chin


Immunomedics Inc. said it has extended its partnership with Roche Holding Ltd. on clinical trials of their combined treatments for patients with metastatic urothelial cancer and metastatic non-small cell lung cancer.

The two companies will look at the efficacy of Immunomedics' Trodelvy treatment in combination with Roche's Tecentriq.

Roche will conduct two open-label, randomized Phase 1b/2 studies that will examine patients who have failed platinum-containing chemotherapy and have begun using Tecentriq and Trodelvy together, as well as patients who use Tecentriq alone. A second study will look at patients who take the combined treatments and docetaxel alone.

Separately, Immunomedics said it will launch a Phase 2 study of Trodelvy for its first patient who has localized triple-negative breast cancer. The treatment will be administered before tumor-removal surgery, the company said. The primary aim of the study will be to show a pathological complete response rate to the treatment, Immunomedics said.


Write to Kimberly Chin at


(END) Dow Jones Newswires

July 13, 2020 17:07 ET (21:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Roche (QX) Charts.